Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

6 Aug 2012

Abstract excerpt

Expression of functional breast cancer susceptibility gene 1 (BRCA1) in human breast and ovarian cancers is associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors. BRCA1 is a nuclear tumor suppressor that is critical for resolving double-strand DNA breaks (DSBs) and interstrand crosslinks (ICLs) by homologous recombination (HR). In vitro, animal and human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22869732
DOI: 10.1073/pnas.1203326109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activationPMID 22869732Read ↗

Hsp90: A New Player in DNA Repair?Semantic proximity Read ↗

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cellsSemantic proximity Read ↗

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistanceSemantic proximity Read ↗

Targeting XRCC1 Deficiency in Breast Cancer for Personalized TherapySemantic proximity Read ↗

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.Semantic proximity Read ↗

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protractionSemantic proximity Read ↗

HSP90 inhibition disrupts telomere maintenance and promotes chromosomal instability (CIN) in cancer cellsSemantic proximity Read ↗

Exploiting DNA repair defects in triple negative breast cancer to improve cell killingSemantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.Semantic proximity Read ↗

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibitionSemantic proximity Read ↗

Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.